Insights from nanomedicine into chloroquine efficacy against COVID-19

Nat Nanotechnol. 2020 Apr;15(4):247-249. doi: 10.1038/s41565-020-0674-9.

Abstract

Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus
  • COVID-19
  • Chloroquine / pharmacokinetics
  • Chloroquine / pharmacology
  • Chloroquine / therapeutic use*
  • Coronavirus Infections / drug therapy*
  • Endocytosis / drug effects
  • Humans
  • Hydrogen-Ion Concentration
  • Hydroxychloroquine / pharmacokinetics
  • Hydroxychloroquine / pharmacology
  • Hydroxychloroquine / therapeutic use*
  • Inflammation
  • Nanomedicine
  • Nanoparticles
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / drug effects
  • Spike Glycoprotein, Coronavirus / metabolism
  • Virion / drug effects
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Hydroxychloroquine
  • Chloroquine

Supplementary concepts

  • COVID-19 drug treatment